Schrodinger Inc. Stock News

When investors think of Bill Gates stocks, they inevitably come up with Microsoft (NASDAQ: MSFT ), the software company he co-founded with Paul Allen in 1975 in Albuquerque. However, as Gates has spen

Schrödinger has a physics-based platform that helps accelerate drug discovery. The company sells its software to other businesses and has its own drug pipeline.

This company uses AI to improve drug discovery for all of the 20 biggest biopharmaceutical companies. Even the most pessimistic analyst thinks the stock could jump nearly 32% over the next 12 months.

I don't think there is any debate on the point that Nvidia (NASDAQ: NVDA ) has established itself as the godfather of AI. As growth accelerates for Nvidia in a big addressable global market, the compa

The transformative power of artificial intelligence ( AI ) — with regards to drug makers and banks to oil companies to every firm that carries out intensive sales activities — is widely known. Ye

Schrödinger is a leading AI drug discovery company with a comprehensive platform used by researchers and scientists worldwide. The company's flagship product, Maestro, integrates various proprietary

See two of the featured stocks from this month's model portfolios.

Schrodinger's stock has performed well this year due to AI hype and strength in its drug discovery business. While the company appears attractively valued from a long-term perspective, the tight finan

There's no foolproof method for making money in the stock market, and, in my view, no one should rely on any one technique for picking stocks. After all, using multiple criteria — including analyzin

Artificial intelligence is changing the drug-discovery process by making it much faster and cheaper.  Traditionally, most biotech stock drug candidates fail.

Many investors, including a significant number of very wealthy individuals and institutions, are becoming enthralled with AI stocks. According to Goldman Sachs (NYSE: GS ), up to $200 billion could be

Second-quarter revenue was down 9% year over year. Schrödinger increased revenue guidance for software revenue but decreased it for drug discovery.

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.62 per share a year ago.

Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.

But some stocks in the biotech category are rising for a reason that's more common with techs, such as chipmaker Nvidia Corp. NASDAQ: NVDA or Microsoft Corp. NASDAQ: MSFT, which has made a significant